Article

Topcon receives FDA approval for OCT technology

Paramus, NJ-Topcon Medical Systems Inc. has received FDA approval for technology that combines Fourier-domain optical coherence tomography (OCT) with a color, non-mydriatic retinal camera.

Paramus, NJ-Topcon Medical Systems Inc. has received FDA approval for technology that combines Fourier-domain optical coherence tomography (OCT) with a color, non-mydriatic retinal camera. The equipment (3D OCT-1000) is the first of its kind, according to the company.

The instrument provides high-resolution, cross-sectional imaging of the retina to assist in the diagnosis and monitoring of pathologies such as retinal detachments, macular holes, age-related macular degeneration, and glaucoma. Among its features are a three-dimensional view of the mapped area and retinal registration of the OCT image and the fundus image.

“By offering a greater number of scans over a large area, the . . . data [from the new technology] provide better delineation of pathology and accurate retinal registration and color fundus images, enabling a more precise comparison of OCT data between patient visits,” said Alexander Walsh, MD, assistant professor of ophthalmology, Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles. “It also allows the practitioner to map the exact location of retinal abnormalities, many of which cannot even be seen with time-domain OCT, and enhances visualization for the purpose of patient education.”

The company has sold more than 300 of the devices outside of the United States, said Paul Iwasaki, president of Topcon Medical Systems. “We are now happy to have the instrument available for our U.S. customers,” he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.